Redefining Immunomodulation with the KAS-X TM Platform
Pioneering therapeutics to rebalance immunity
ABOUT
Kaass Discovery develops potential first-in-class immunomodulators validated through independent, blinded preclinical studies conducted with global CRO partners.
​
Operational since 2020, this privately held Norwegian biotechnology company works as a lean, asset-focused organization with flexibility for strategic partnerships and global growth.​​​
PIPELINE
Targeting an upstream immune axis unaddressed by existing therapies
​
Our anchor program in rheumatoid arthritis is supported by compelling in vivo data. Building on this foundation, we are exploring additional indications where immune dysregulation plays a central role.​
​​
- Robust efficacy and favourable safety in prophylactic and therapeutic CIA. Studies conducted by Charles River Laboratories.​
​
- Significant improvement at key time points in other undisclosed diseases. ​
​​​
- Consistent safety and tolerability across all completed studies.
​​
​​
SCIENTIFIC DEVELOPMENT
& SUPPORT
Our programs are advanced with the support of trusted CROs and research providers:
LEGAL & IP COUNSEL
We are supported by leading global intellectual property and legal advisors, including Cooley LLP and Dehns.
FUNDING & SUPPORT
We are grateful for the support of leading innovation agencies and programs:
TEAM
Dr. Anita Kåss, MBChB (Hons) PhD is the founder and CEO of Kaass Discovery. She has received numerous accolades including the Arthritis Research UK Award at the University of Liverpool, Doctor of the Year by the Telemark Medical Association, and she was one of the first beneficiaries of the Women TechEU programme under Horizon Europe in 2021.
Preben Hjallum is the COO at Kaass Discovery. He is responsible for corporate development, partnerships, and overall business strategy, ensuring that Kaass Discovery advances efficiently as a lean, asset-focused biotech. Preben brings experience from leadership roles across several health companies, providing a broad network and cross-sector perspective that support the company’s global partnering ambitions.